Trust Company’s Novartis NVS Stock Holding History

Trust Company’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.5K	Buy	558 +99	+22%	+$14.8K	0.01%	242
2026 Q1	$70.1K	Hold	459	–	–	0.01%	265
2025 Q4	$63.3K	Buy	459 +159	+53%	+$20.8K	0.01%	265
2025 Q3	$38.5K	Hold	300	–	–	﹤0.01%	233
2025 Q2	$36.3K	Hold	300	–	–	﹤0.01%	237
2025 Q1	$33.4K	Hold	300	–	–	﹤0.01%	250
2024 Q4	$29.2K	Buy	300 +100	+50%	+$10.7K	﹤0.01%	256
2024 Q3	$23K	Hold	200	–	–	﹤0.01%	252
2024 Q2	$21.3K	Hold	200	–	–	﹤0.01%	245
2024 Q1	$19.3K	Hold	200	–	–	﹤0.01%	253
2023 Q4	$20.2K	Hold	200	–	–	﹤0.01%	237
2023 Q3	$20.4K	Hold	200	–	–	﹤0.01%	235
2023 Q2	$20.2K	Hold	200	–	–	﹤0.01%	240
2023 Q1	$18.4K	Hold	200	–	–	﹤0.01%	238
2022 Q4	$18K	Hold	200	–	–	﹤0.01%	231
2022 Q3	$15K	Hold	200	–	–	﹤0.01%	237
2022 Q2	$17K	Hold	200	–	–	﹤0.01%	245
2022 Q1	$18K	Hold	200	–	–	﹤0.01%	252
2021 Q4	$17K	Hold	200	–	–	﹤0.01%	237
2021 Q3	$16K	Hold	200	–	–	﹤0.01%	235
2021 Q2	$18K	Hold	200	–	–	0.01%	232
2021 Q1	$17K	Sell	200 -32	-14%	-$2.87K	0.01%	242
2020 Q4	$22K	Buy	232 +32	+16%	+$2.8K	0.02%	205
2020 Q3	$17K	Hold	200	–	–	0.01%	231
2020 Q2	$17K	Hold	200	–	–	0.02%	216
2020 Q1	$16K	Hold	200	–	–	0.02%	202
2019 Q4	$19K	Hold	200	–	–	0.02%	215
2019 Q3	$17K	Hold	200	–	–	0.02%	225
2019 Q2	$18K	Sell	200 -23	-10%	-$1.95K	0.02%	212
2019 Q1	$19K	Hold	223	–	–	0.01%	241
2018 Q4	$17K	Hold	223	–	–	0.01%	230
2018 Q3	$17K	Hold	223	–	–	0.01%	237
2018 Q2	$15K	Hold	223	–	–	0.01%	255
2018 Q1	$16K	Hold	223	–	–	0.01%	246
2017 Q4	$17K	Sell	223 -94	-30%	-$7.09K	0.01%	245
2017 Q3	$24K	Hold	317	–	–	0.01%	187
2017 Q2	$24K	Sell	317 -343	-52%	-$24.3K	0.01%	205
2017 Q1	$44K	Sell	660 -271	-29%	-$18.1K	0.02%	187
2016 Q4	$61K	Sell	931 -10,573	-92%	-$686K	0.03%	164
2016 Q3	$814K	Sell	11,504 -33,635	-75%	-$2.45M	0.36%	73
2016 Q2	$3.34M	Sell	45,139 -249	-0.5%	-$17.2K	1.27%	30
2016 Q1	$2.95M	Buy	45,388 +3,962	+10%	+$270K	1.35%	34
2015 Q4	$3.19M	Buy	41,426 +6,817	+20%	+$542K	1.48%	24
2015 Q3	$2.85M	Buy	34,609 +16,144	+87%	+$1.44M	1.62%	21
2015 Q2	$1.63M	Sell	18,465 -4,403	-19%	-$404K	1.02%	43
2015 Q1	$2.02M	Buy	+22,868	New	+$2.03M	1.28%	23

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Trust Company's NVS Position: Q2 2026 in Review

Trust Company increased its Novartis (NVS) stake by 22% in Q2 2026, buying an estimated $14.8K and bringing the position to 558 shares worth $87.5K. The position accounts for 0.01% of the portfolio, ranked #242.

Trust Company first reported a position in NVS in Q1 2015 and has held it in 46 quarters since. The position peaked at $3.34M in Q2 2016. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Trust Company held 558 shares of Novartis worth $87.5K as of Q2 2026.
Trust Company bought 99 Novartis shares in Q2 2026, an estimated $14.8K.
Novartis made up 0.01% of Trust Company's portfolio in Q2 2026, its #242 holding.
Trust Company first reported a position in Novartis in Q1 2015 and has held it in 46 quarters since.
Trust Company's Novartis position peaked at $3.34M in Q2 2016.
1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.